Trial watch: dendritic cell vaccination for cancer immunotherapy

Autor:	Jenny Sprooten, Jolien Ceusters, An Coosemans, Patrizia Agostinis, Steven De Vleeschouwer, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Abhishek D. Garg
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	antigen cross-presentation damps immune checkpoint blockers plasmacytoid dendritic cells tlr signaling tumor-infiltrating lymphocytes clinical trial Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	OncoImmunology, Vol 8, Iss 11 (2019)
Druh dokumentu:	article
ISSN:	2162-402X 2162402X
DOI:	10.1080/2162402X.2019.1638212
Popis:	Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/c5ccb54faf214b31843b0797a54eda70 Zobrazit plný text záznamu View record in DOAJ